First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agent

To evaluate the feasibility of first‐pass contrast‐enhanced magnetic resonance angiography (MRA) using ferumoxytol in humans.

[1]  Martin R Prince,et al.  Blood pool MR angiography of aortic stent-graft endoleak. , 2004, AJR. American journal of roentgenology.

[2]  C. Bremer,et al.  Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebo-controlled clinical phase i study. , 2004, Radiology.

[3]  H. Lamb,et al.  Three‐dimensional navigator coronary MRA with the aid of a blood pool agent in pigs: Improved image quality with inclusion of the contrast agent first‐pass , 2003, Journal of magnetic resonance imaging : JMRI.

[4]  M. Prince,et al.  A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. , 2003, Journal of X-ray science and technology.

[5]  D. Pennell,et al.  Initial experience with the intravascular contrast agent NC100150‐injection (Clariscan®) for breath‐hold and navigator‐gated magnetic resonance coronary artery imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[6]  Christina J. Herold,et al.  MRA of the lower extremities in patients with pulmonary embolism using a blood pool contrast agent: Initial experience , 2002, Journal of magnetic resonance imaging : JMRI.

[7]  W. Heindel,et al.  First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. , 2002, Academic radiology.

[8]  B. Hamm,et al.  Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium. , 2002, Radiology.

[9]  J. Finn,et al.  Three‐dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B‐22956/1 , 2001, Journal of magnetic resonance imaging : JMRI.

[10]  Improved cine cardiovascular magnetic resonance using Clariscan (NC100150 injection). , 2001, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[11]  B Hamm,et al.  New generation of monomer‐stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: Preclinical results in rats and rabbits , 2000, Journal of magnetic resonance imaging : JMRI.

[12]  A. Bjørnerud,et al.  NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.

[13]  Guang-Zhong Yang,et al.  First‐pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection , 1999, Journal of magnetic resonance imaging : JMRI.

[14]  A de Roos,et al.  Blood pool contrast agents for cardiovascular MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.

[15]  S. Schoenberg,et al.  Contrast agents for MRA: Future directions , 1999, Journal of magnetic resonance imaging : JMRI.

[16]  T M Grist,et al.  Contrast‐enhanced MR angiography of the carotid bifurcation , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  T. Allkemper,et al.  Contrast‐enhanced 3D‐MRA of the upper abdomen with a bolus‐injectable SPIO (SH U 555 A) , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  D C Peters,et al.  Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.

[19]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[20]  D. Revel,et al.  Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: Experimental study in rabbits , 1997, Journal of magnetic resonance imaging : JMRI.

[21]  Yoshimi Anzai,et al.  MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent , 1997, Journal of magnetic resonance imaging : JMRI.

[22]  D. Mitchell.  MR imaging contrast agents — what's in a name? , 1997, Journal of magnetic resonance imaging : JMRI.

[23]  Evaluation of portal MR angiography using superparamagnetic iron oxide , 1997, Journal of magnetic resonance imaging : JMRI.

[24]  R Frayne,et al.  Time‐resolved contrast‐enhanced 3D MR angiography , 1996, Magnetic resonance in medicine.

[25]  S. Saini,et al.  MR contrast material for vascular enhancement: value of superparamagnetic iron oxide. , 1996, AJR. American journal of roentgenology.

[26]  A E Stillman,et al.  Ultrasmall superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients. , 1996, Journal of computer assisted tomography.

[27]  E. Yucel.  MR angiography for evaluation of abdominal aortic aneurysm: has the time come? , 1994, Radiology.

[28]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[29]  M. Prince.  Gadolinium-enhanced MR aortography. , 1990, Radiology.

[30]  R. Weissleder,et al.  Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. , 1994, AJR. American journal of roentgenology.